Informed Consent for Medical Device Clinical Trials: 21 CFR 50, EFIC & EU MDR Article 63
Complete guide to informed consent in medical device clinical trials: 21 CFR Part 50 & Part 812, 50.22 minimal-risk waiver, 50.24 EFIC, and EU MDR Article 63.
In medical device clinical investigations, informed consent is not merely a signed form in the Trial Master File (TMF); it is a legally mandated, continuous communication process governed by stringent statutory and regulatory standards. Whether conducting an early feasibility study under a U.S. Investigational Device Exemption (IDE) or a pivotal clinical investigation under EU MDR 2017/745 Article 62, obtaining legally effective informed consent is a non-negotiable prerequisite for enrolling human subjects.
Yet, informed consent for medical devices is frequently mishandled because clinical operations teams often default to pharmaceutical clinical trial templates. Drug trials and device trials operate under fundamentally different physical, surgical, and post-trial realities:
- Device vs. Procedure Risk Conflation: Unlike an oral drug, a device investigation often entails surgical delivery, implantation, device calibration, software updates, and potential explantation. Conflating the surgical delivery risks with the device's intrinsic mechanical or electrical risks confuses subjects and violates regulatory clarity standards.
- The Implant Withdrawal Dilemma: If a subject withdraws consent in a drug trial, they stop taking the pill. If a subject withdraws consent in an implantable device trial, the device remains inside their body. The Informed Consent Form (ICF) must pre-specify what happens to ongoing clinical monitoring, device explantation risks, and data retention.
- Harmonization and Regulatory Divergence: Clinical teams frequently confuse U.S. FDA requirements under 21 CFR Part 50 with HHS Common Rule provisions (45 CFR Part 46), or fail to account for the mandatory EU MDR Article 63 requirements—such as dual investigator-subject signatures, statutory damage compensation disclosures, and mandatory public lay summaries in EUDAMED.
Disambiguation Note: This guide covers informed consent requirements for investigational medical device clinical studies under Good Clinical Practice (GCP), ISO 14155:2026, 21 CFR Part 50 / Part 812, and EU MDR Articles 62–69. It does not cover Institutional Review Board (IRB) administrative organization under 21 CFR Part 56, general HHS Common Rule compliance for non-FDA funded university research, commercial GDPR / HIPAA data-privacy authorizations for marketed health software, or postmarket patient labeling such as EU MDR Article 18 implant cards.
Direct Answer: If your team is preparing a pivotal trial for an implantable device running concurrently under a U.S. IDE and EU MDR Article 62:
- U.S. Requirements (21 CFR Part 50 & Part 812): You cannot enroll any subject without legally effective informed consent documented by an IRB-approved written consent form signed and dated by the subject or their legally authorized representative (LAR), with a copy provided to the signer (21 CFR 50.20, 50.27). The ICF must incorporate the 8 basic elements of 21 CFR 50.25(a), applicable additional elements of 50.25(b), and the mandatory verbatim ClinicalTrials.gov statement of 50.25(c). Consent can only be waived by an IRB for minimal-risk investigations meeting the 5 criteria of 21 CFR 50.22 (effective January 22, 2024). Planned emergency research without consent requires the Exception From Informed Consent (EFIC) pathway under 21 CFR 50.24, which for devices mandates a separate full IDE application (21 CFR 812.20(a)(1)), prior written FDA authorization before enrollment (21 CFR 812.20(a)(4)(i)), prominent cover-sheet labeling, community consultation, and an independent Data Monitoring Committee (DMC).
- EU MDR Requirements (MDR Articles 62 & 63): Under MDR Article 62(4)(f), obtaining consent in accordance with Article 63 is a statutory condition for conducting the trial. Article 63 mandates requirements beyond U.S. law: the consent form must be signed and dated by both the person conducting the informed consent interview and the subject/representative (Article 63(1)); the subject must be given adequate time to decide; the form must disclose the national damage compensation system established under Article 69 (Article 63(2)(d)); the form must state the Single Identification Number (CIV-ID) and describe results availability (Article 63(2)(e)); and subjects must be explicitly informed that the clinical investigation report and a layperson summary will be published in EUDAMED pursuant to Article 77(5) regardless of study outcome (Article 63(6)).
- Implant Withdrawal & Drug-Template Adaptation: Do not copy a drug ICF template. For implantable devices, the ICF must explicitly distinguish procedural surgical risks from ongoing device-related risks, provide clear terms for post-withdrawal clinical care (since data collected prior to withdrawal is retained under MDR Article 62(5) and FDA guidance, but the physical implant may not be safely explanted), and outline long-term safety monitoring.
What Must a US Device Informed Consent Form Contain Under 21 CFR 50.25?
Under U.S. FDA regulations governing human subject protection, 21 CFR 50.25 establishes the required content for any informed consent document. For medical device clinical investigations conducted under an IDE (21 CFR Part 812), consent forms must be submitted to the FDA as part of the IDE application (21 CFR 812.20(b)(11)) and included in the investigational plan (21 CFR 812.25(g)).
+----------------------------------------------------------------------------------------------------+
| 21 CFR PART 50 INFORMED CONSENT ARCHITECTURE |
+----------------------------------------------------------------------------------------------------+
| |
| [ 21 CFR 50.25(a) - 8 BASIC REQUIRED ELEMENTS ] |
| 1. Research Statement, Purpose, Duration, Procedures, Experimental Identification |
| 2. Foreseeable Risks and Discomforts (Device vs. Surgical Procedure) |
| 3. Expected Benefits to Subject or Others |
| 4. Appropriate Alternative Procedures or Treatments |
| 5. Confidentiality Extent & FDA Record Inspection Disclosure |
| 6. Compensation & Medical Treatment for Research-Related Injury (> Minimal Risk) |
| 7. Contact Information (Trial Questions, Subject Rights, Injury) |
| 8. Voluntary Participation, Right to Refuse / Discontinue Without Penalty |
| |
| + |
| |
| [ 21 CFR 50.25(b) - 6 ADDITIONAL ELEMENTS (WHEN APPROPRIATE) ] |
| 1. Unforeseeable Risks (Subject, Embryo, or Fetus) |
| 2. Investigator Termination Circumstances Without Subject Consent |
| 3. Additional Costs to Subject Resulting from Participation |
| 4. Consequences of Subject Withdrawal & Orderly Termination Procedures |
| 5. Significant New Findings Notification (Relating to Willingness to Continue) |
| 6. Approximate Number of Subjects Involved |
| |
| + |
| |
| [ 21 CFR 50.25(c) - MANDATORY REGISTRY STATEMENT ] |
| Verbatim 4-sentence statutory statement for Applicable Clinical Trials on ClinicalTrials.gov |
| |
+----------------------------------------------------------------------------------------------------+
The 8 Basic Elements (21 CFR 50.25(a))
Every informed consent form presented to prospective device trial subjects must contain the following eight core elements:
- Research Statement and Procedures (50.25(a)(1)): A clear explanation that the study involves research, the specific purposes of the trial, expected duration of subject participation, a description of the procedures to be followed, and the explicit identification of any procedures that are experimental. For medical devices, this includes specifying whether the device is unapproved, used off-label, or modified from a cleared version.
- Foreseeable Risks and Discomforts (50.25(a)(2)): A description of any reasonably foreseeable risks or discomforts. In device investigations, this requires distinguishing between risks inherent to the investigational device (e.g., lead fracture, biomaterial thrombosis, battery depletion) and risks related to the surgical or delivery procedure (e.g., vascular puncture hematoma, anesthesia risks).
- Reasonably Expected Benefits (50.25(a)(3)): A description of any benefits to the subject or to others that may reasonably be expected. Consent documents must never overstate therapeutic benefits or promise a cure; if the study is an early feasibility study (EFS) or first-in-human (FIH) trial, the ICF must clearly state that direct benefit may not occur.
- Alternative Procedures or Treatments (50.25(a)(4)): A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject. This includes standard-of-care medical therapies, commercially cleared alternative devices, or watchful waiting.
- Confidentiality and FDA Inspection (50.25(a)(5)): A statement describing the extent to which confidentiality of identifying records will be maintained, containing an explicit note that the U.S. Food and Drug Administration may inspect study records.
- Injury Compensation and Medical Treatment (50.25(a)(6)): For research involving more than minimal risk, an explanation as to whether any compensation and medical treatments are available if injury occurs, what they consist of, or where further information may be obtained.
- Contact Information (50.25(a)(7)): An explanation of whom to contact for answers to pertinent questions about the research and subjects' rights, and whom to contact in the event of a research-related injury. This requires distinct contact details for the study investigator and the independent IRB.
- Voluntary Participation (50.25(a)(8)): A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits.
The 6 Additional Elements (21 CFR 50.25(b))
When appropriate to the clinical investigation, the ICF must include one or more of the following additional elements:
- Unforeseeable Risks (50.25(b)(1)): A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) that are currently unforeseeable. Essential for novel biomaterials or novel energy-delivery mechanisms.
- Investigator Termination (50.25(b)(2)): Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent (e.g., protocol non-compliance, anatomical incompatibility identified intraoperatively, device failure).
- Additional Costs (50.25(b)(3)): Any additional costs to the subject that may result from participation. Sponsors must clarify whether the investigational device, surgical implantation, diagnostic scans (CT/MRI), and follow-up visits are covered by the study or billed to the patient's insurance.
- Orderly Termination and Withdrawal Consequences (50.25(b)(4)): The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation. Crucial for active implants (e.g., pacemakers, neuromodulators, orthopedics) where device deactivation, surgical explant, or long-term safety tracking is necessary.
- Significant New Findings (50.25(b)(5)): A statement that significant new findings developed during the course of the research that may relate to the subject's willingness to continue participation will be provided to the subject (e.g., unexpected safety signals, competitor recalls, UADE reporting findings).
- Subject Enrollment Count (50.25(b)(6)): The approximate number of subjects involved in the study.
The Mandatory ClinicalTrials.gov Statement (21 CFR 50.25(c))
Added by FDA final rule in 2011 (76 FR 270), 21 CFR 50.25(c) mandates that for every "applicable clinical trial" (under 42 U.S.C. 282(j)(1)(A), generally a prospective clinical study of health outcomes comparing a device intervention against a control; small feasibility trials and prototype-device trials with feasibility-focused primary outcomes are excluded), the consent form must include the exact verbatim statement:
"A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time."
Modifying, paraphrasing, or shortening this 4-sentence statement is a direct regulatory violation. Clinical teams can review registry landscape requirements in our ClinicalTrials.gov medical device trials guide.
FDA August 2023 Final Guidance: Key Operational Expectations
In August 2023, the FDA issued its final guidance, Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors (superseding the 1998 guidance and finalizing the 2014 draft). Key takeaways for medical device sponsors include:
- Process Over Form: Consent is an ongoing dialogue, not a static administrative milestone. Information must be delivered in language understandable to the subject or LAR (21 CFR 50.20); the guidance devotes FAQ sections to low-literacy, limited-English-proficiency, and impaired-consent-capacity subjects, but sets no numeric reading-level standard.
- No Key-Information Mandate (Yet): The revised Common Rule (45 CFR 46.116(a)(5)) requires a concise, front-loaded "key information" presentation, but current 21 CFR Part 50 contains no key-information or broad-consent provision, and the 2023 guidance does not prescribe a key-information section. Teams writing one form for both regimes should treat front-loading as institutional best practice, not a federal mandate.
- Submission to FDA: For significant risk (SR) device investigations, copies of all forms and informational materials to be provided to subjects to obtain informed consent must be included in the IDE application to FDA (21 CFR 812.20(b)(11)).
Who Signs, Who Witnesses, and What Does the Short-Form Method Require Under 21 CFR 50.27?
Documenting informed consent under U.S. law is governed by 21 CFR 50.27. The regulation provides two distinct documentation pathways:
+----------------------------------------------------------------------------------------------------+
| 21 CFR 50.27 CONSENT DOCUMENTATION PATHWAYS |
+----------------------------------------------------------------------------------------------------+
| |
| [ PATHWAY A: WRITTEN LONG FORM (50.27(a), 50.27(b)(1)) ] |
| * Standard mechanism for literate subjects in a language they understand. |
| * IRB-approved written document embodying all 50.25 elements. |
| * Read by or read to the subject / Legally Authorized Representative (LAR). |
| * Signed and dated by subject or LAR at the time of consent. |
| * A copy of the signed form is given to the person signing. |
| |
| ------------------------------------------------------------------------------------------------ |
| |
| [ PATHWAY B: SHORT FORM ORAL PRESENTATION (50.27(b)(2)) ] |
| * Used for non-English speaking or illiterate subjects when translated long form is unavailable. |
| * Requires THREE distinct documents / signatures: |
| 1. Short Form (in subject's language): Signed & dated by Subject/LAR AND Impartial Witness. |
| 2. Written Summary (in presenter's language): Signed & dated by Presenter AND Impartial Witness.|
| 3. Subject Receives: Copy of the signed Short Form + Copy of the signed Summary. |
| |
+----------------------------------------------------------------------------------------------------+
The Standard Long-Form Method (21 CFR 50.27(b)(1))
Under the standard long-form process:
- The subject or their Legally Authorized Representative (LAR) is given adequate time to read and review the IRB-approved document.
- The investigator or designated study staff conducts a comprehensive discussion answering all subject questions.
- The subject or LAR signs and dates the consent form.
- A copy of the signed and dated form is provided to the person who signed it.
The Short-Form Oral Presentation Method (21 CFR 50.27(b)(2))
When enrolling a subject who does not understand English (and an IRB-approved translated long form is not yet available) or an illiterate subject, investigators may use the short-form method under strict procedural controls:
| Document / Step | Content / Language | Who Signs and Dates? | Who Receives a Copy? |
|---|---|---|---|
| Short Form Document | States that the required elements of informed consent have been presented orally; written in a language understandable to the subject. | Subject (or LAR) and Impartial Witness | Subject or LAR |
| Written Summary | The IRB-approved English consent document (or summary) describing what is presented orally. | Person Obtaining Consent (Presenter) and Impartial Witness | Subject or LAR |
| Oral Presentation | Spoken presentation of the summary assisted by a qualified medical interpreter. | N/A (Witness must observe the entire presentation). | N/A |
Critical Compliance Rule: The person obtaining consent (the investigator or study coordinator) cannot serve as the witness. The witness must be independent and fluent in both the language of the presenter and the language of the subject.
Legally Authorized Representatives (LAR) and Pediatric Assent
Under 21 CFR 50.3(l), an LAR is an individual or judicial body authorized under applicable state or local law to consent on behalf of a prospective subject to their participation in the clinical investigation.
- State Law Primacy: The FDA does not define who qualifies as an LAR; qualification is strictly determined by the statute of the state or jurisdiction where the trial site is located (e.g., healthcare power of attorney, legal guardian, next-of-kin hierarchy).
- Pediatric Device Trials (21 CFR Part 50 Subpart D): Enrolling children in medical device studies requires parental or guardian permission (21 CFR 50.55) combined with child assent (for children capable of providing assent based on age, maturity, and psychological state).
Electronic Informed Consent (eIC) and 21 CFR Part 11
Under the joint FDA and OHRP guidance Use of Electronic Informed Consent in Clinical Investigations (December 2016, 81 FR 90855, Docket FDA-2015-D-0390), sponsors may use electronic media (tablets, web portals, interactive videos) to deliver and document consent:
- Part 11 Compliance: The electronic system capturing signatures must fully comply with 21 CFR Part 11 (electronic records, secure user authentication, audit trails, and cryptographically linked signatures).
- Identity Verification: The system must verify the identity of the person signing electronically.
- Subject Access: Subjects must be given the option to receive a paper copy of their signed electronic consent document.
When Can Consent Be Waived or Altered: The Five Criteria of 21 CFR 50.22 vs. Emergency 50.23
Historically, the FDA strictly prohibited IRBs from waiving or altering informed consent for minimal-risk research, creating a major divergence between FDA regulations and the HHS Common Rule (45 CFR 46.116). This regulatory conflict was resolved by statutory amendment and rulemaking.
+----------------------------------------------------------------------------------------------------+
| THE 21 CFR 50.22 MINIMAL-RISK WAIVER: THE 5 STATUTORY CRITERIA |
| (Final Rule: 88 FR 88228, Dec 21, 2023; Effective Jan 22, 2024) |
+----------------------------------------------------------------------------------------------------+
| |
| [ CRITERION 1 (50.22(a)): MINIMAL RISK ] |
| The clinical investigation involves no more than minimal risk to the subjects. |
| |
| [ CRITERION 2 (50.22(b)): PRACTICABILITY ] |
| The investigation could not practicably be carried out without the requested waiver/alteration. |
| |
| [ CRITERION 3 (50.22(c)): IDENTIFIABLE INFORMATION / BIOSPECIMENS ] |
| If it uses identifiable private information or biospecimens, the investigation could not |
| practicably be carried out without using them in an identifiable format. |
| |
| [ CRITERION 4 (50.22(d)): RIGHTS AND WELFARE ] |
| The waiver or alteration will not adversely affect the rights and welfare of the subjects. |
| |
| [ CRITERION 5 (50.22(e)): PERTINENT INFORMATION POST-PARTICIPATION ] |
| Whenever appropriate, the subjects or LARs will be provided with additional pertinent |
| information after participation. |
| |
+----------------------------------------------------------------------------------------------------+
The 21 CFR 50.22 Minimal-Risk Waiver Rule
Section 3024 of the 21st Century Cures Act (enacted December 2016) amended sections 520(g)(3) and 505(i)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to permit FDA consent waivers for minimal-risk research. Following proposed rulemaking (83 FR 57378, Nov 15, 2018), the FDA published its final rule, Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations (88 FR 88228–88249, Docket FDA-2018-N-2727, RIN 0910-AH52), adding 21 CFR 50.22 effective January 22, 2024.
Under 21 CFR 50.22, an IRB may approve a consent procedure that does not include or alters some or all of the elements of informed consent, or waive the requirement to obtain informed consent entirely, provided the IRB finds and documents that all five criteria above are satisfied.
Device Applicability: What Qualifies vs. What Fails
| Device Study Type | Qualifies for 50.22 Waiver? | Regulatory Rationale |
|---|---|---|
| Retrospective EHR Device Registry Study | YES | Minimal risk; purely observational; infeasible to obtain re-consent from thousands of historical patients. |
| Secondary Analysis of De-Identified Leftover Specimens (IVD) | YES | Minimal risk; specimens collected for routine clinical care; meets Criterion 5. |
| Non-Invasive Diagnostic Sensor (NSR) | POTENTIALLY (Alteration) | Minimal risk, but physical subject interaction usually permits obtaining consent; alteration of minor elements possible if full disclosure biases behavioral testing. |
| Significant Risk (SR) Implantable Device (Pivotal IDE) | NO (NEVER) | By definition, an SR device involves more than minimal risk under 21 CFR 812.3(m). |
| Interventional Surgical Catheter Investigation | NO (NEVER) | Involves invasive procedural risk exceeding minimal risk standard. |
Single Emergency Use Under 21 CFR 50.23
For an individual patient facing an immediate life-threatening condition where no standard acceptable treatment is available and time does not permit obtaining prospective consent, 21 CFR 50.23 provides an emergency exemption:
- Two-Physician Certification: Before using the unapproved device, both the investigator and a licensed physician who is not participating in the clinical investigation must certify in writing that:
- The subject is confronted by a life-threatening situation necessitating the use of the test article;
- Informed consent cannot be obtained because of an inability to communicate with or obtain legally effective consent from the subject;
- Time is not sufficient to obtain consent from the subject's LAR; and
- No alternative method of approved or generally recognized therapy is available that provides an equal or greater likelihood of saving the subject's life.
- Special Case (50.23(b)): If immediate use is required to preserve life and time does not allow prior independent physician assessment, the investigator may proceed but must have the independent physician evaluate the case within 5 working days.
- 5-Working-Day Reporting Clock: Under 21 CFR 50.23(c) and 21 CFR 812.150(a)(5), the investigator must submit the written certification to the reviewing IRB within 5 working days after the use of the device.
How Does EFIC Emergency Research Work for Devices Under 21 CFR 50.24 and the Part 812 Separate-IDE Rule?
When conducting planned clinical research in acute emergency settings—such as out-of-hospital cardiac arrest, severe traumatic brain injury, or acute hemorrhagic shock—subjects are unconscious and family members are rarely immediately available within the therapeutic window. In these situations, prospective informed consent is impossible.
To enable life-saving research while protecting vulnerable subjects, 21 CFR 50.24 establishes the Exception From Informed Consent (EFIC) pathway.
+----------------------------------------------------------------------------------------------------+
| 21 CFR 50.24 EFIC DEVICE REGULATORY GATEWAY |
+----------------------------------------------------------------------------------------------------+
| |
| [ STATUTORY GATEWAY: 21 CFR PART 812 OVERLAY ] |
| * 21 CFR 812.20(a)(1): All 50.24 device studies are automatically Significant Risk (SR). |
| * 21 CFR 50.24(d): MUST be submitted as a SEPARATE IDE (never an amendment to existing IDE). |
| * 21 CFR 812.20(a)(4)(i): NO ENROLLMENT WITHOUT PRIOR WRITTEN FDA AUTHORIZATION (30-day clock). |
| * 21 CFR 812.20(a)(4)(ii): IDE Cover Sheet MUST prominently state "Subject to 21 CFR 50.24". |
| |
| | |
| v |
| |
| [ CORE EFIC MANDATES (21 CFR 50.24(a)) ] |
| 1. Life-threatening condition + unproven/unsatisfactory standard treatments. |
| 2. Direct prospect of benefit + risk/benefit ratio comparable/favorable to standard care. |
| 3. Impracticable to conduct study with prospective consent (narrow therapeutic window). |
| 4. Independent Data Monitoring Committee (DMC) MANDATORY. |
| 5. Community Consultation (Town halls, public forums, patient advocacy groups). |
| 6. Public Disclosure (Pre-study announcement + Post-study results/demographics disclosure). |
| 7. Sponsor Submissions to FDA Docket 95S-0158 (Dockets Management Staff). |
| 8. Family Notification & Opt-Out Mechanism (Contact LAR within window; provide opt-out tools). |
| |
+----------------------------------------------------------------------------------------------------+
The 7 Core EFIC Safeguards (21 CFR 50.24(a))
Under 21 CFR 50.24(a), an IRB (with concurrence of a licensed physician member or consultant not participating in the study) may approve an emergency research protocol without prospective informed consent only after documenting that:
- Life-Threatening Situation: The human subjects are in a life-threatening situation, available treatments are unproven or unsatisfactory, and collection of valid scientific evidence is necessary to determine the safety and effectiveness of the intervention.
- Obtaining Consent Not Feasible: Obtaining informed consent is not feasible because the subjects cannot give consent due to their medical condition, the intervention must be administered before consent from an LAR is feasible, and there is no reasonable way to prospectively identify likely qualifying individuals.
- Prospect of Direct Benefit: Participation in the research holds the prospect of direct benefit to the subjects.
- Impracticability: The clinical investigation could not practicably be carried out without the waiver.
- Community Consultation & Public Disclosure: The sponsor must conduct active consultation with representatives of the communities in which the trial will be conducted, publicly disclose plans for the investigation and risks prior to study initiation, and publicly disclose study results and demographic characteristics of enrolled subjects after study completion.
- Independent DMC: The protocol must establish an independent Data Monitoring Committee (DMC / DSMB) to oversee the investigation.
- Contact Commitments: The investigator commits to attempting to contact a family member or LAR within the therapeutic window to give them the opportunity to object to enrollment. If a subject is enrolled without consent, the investigator must inform the subject, LAR, or family member at the earliest feasible opportunity.
The Part 812 Device-Specific EFIC Overlay
The regulatory hurdle for running an EFIC device study under 21 CFR Part 812 is significantly higher than for standard clinical trials:
- Automatic Significant Risk (812.20(a)(1)): An investigation subject to 21 CFR 50.24 is automatically classified as a Significant Risk (SR) investigation. Non-Significant Risk (NSR) determinations are legally impossible under EFIC.
- Prior Written FDA Authorization (812.20(a)(4)(i)): A sponsor shall not begin an investigation subject to 50.24 without prior written authorization from the FDA. FDA makes its determination within a 30-day review period.
- Cover Sheet Labeling (812.20(a)(4)(ii)): The IDE application cover sheet must prominently state that the investigation is subject to 21 CFR 50.24.
- Mandatory Separate IDE (50.24(d)): If a sponsor already holds an approved IDE for a device (e.g., for elective catheterization), an EFIC study for the same device (e.g., in cardiac arrest) cannot be submitted as an IDE supplement or protocol amendment. It must be submitted as an entirely separate IDE application.
- FDA Docket 95S-0158 Submissions: As detailed on FDA's IDE Informed Consent guidance page, sponsors must submit copies of all community consultation and public disclosure materials to the FDA Dockets Management Staff (Docket No. 95S-0158).
Real-World Device EFIC Case Studies
Emergency research under EFIC is rare and heavily scrutinized. Two device investigations registered on ClinicalTrials.gov show how the pathway appears in practice - one EFIC-native from inception, and one randomized trial in which EFIC operates as a fallback within a consent hierarchy:
+----------------------------------------------------------------------------------------------------+
| |
| NOTABLE MEDICAL DEVICE EFIC INVESTIGATIONS (REGISTRY RECORDS) |
| |
| 1. RECOVER IV Trial (NCT05506449 - Abiomed) |
| * Device: Impella-based hemodynamic support started before PCI vs. guideline- |
| directed standard care. |
| * Indication: STEMI with cardiogenic shock. |
| * Design: Prospective, multicenter, randomized, open-label, adaptive. |
| * EFIC role: Fallback only - subjects able to consent, or with an LAR present, |
| are consented; subjects unable to consent with no LAR present may be |
| randomized under EFIC. Terminated early after 4 participants enrolled. |
| |
| 2. Ringer Perfusion Balloon Catheter Study (NCT04849169 - Vascular Solutions) |
| * Device: Perfusion balloon catheter managing a coronary artery perforation |
| during PCI while maintaining distal perfusion. |
| * Design: Prospective, multicenter, single-arm EFIC investigation (up to 15 |
| sites, 30 participants); completed November 2023. |
| * EFIC rationale (registry record): no reasonable way to prospectively |
| identify eligible patients, and a coronary perforation must be controlled |
| immediately, leaving no time for subject or LAR consent; patients notified |
| of enrollment as soon as feasible. |
+----------------------------------------------------------------------------------------------------+
What Does the EU MDR Require Under Article 63 That US Forms Do Not Cover?
For clinical investigations conducted in the European Union to demonstrate conformity under Regulation (EU) 2017/745 (MDR), informed consent is governed by Article 62(4)(f) and Article 63.
MDR Article 63 establishes a legal regime that is in many respects significantly more demanding than U.S. 21 CFR Part 50.
+----------------------------------------------------------------------------------------------------+
| EU MDR ARTICLE 63 STATUTORY CONSENT MANDATES |
+----------------------------------------------------------------------------------------------------+
| |
| [ ARTICLE 63(1) - EXECUTION & TIMING MANDATES ] |
| * Dual Signatures: Signed & dated by BOTH the interviewer (investigator) AND the subject/LAR. |
| * Impartial Witness: Mandatory if the subject is unable to write (e.g., physical disability). |
| * Adequate Time: Subject must be given adequate time to consider participation. |
| |
| [ ARTICLE 63(2) - MANDATORY INFORMATIONAL DISCLOSURES ] |
| * Clear Lay Language: Comprehensive, concise, clear, relevant, and understandable to a layperson. |
| * Rights & Guarantees: Unconditional right to refuse/withdraw without detriment (Art. 62(5)). |
| * Damage Compensation: Explicit disclosure of the Article 69 national compensation system/policy. |
| * Registry Identity: Single Identification Number (CIV-ID / CIV ID under Article 70(1)). |
| |
| [ ARTICLE 63(6) - RESULTS & LAY SUMMARY PUBLICATION PROMISE ] |
| * Explicit notice that the Clinical Investigation Report and a Layperson Summary will be |
| submitted to EUDAMED (Article 73 / Article 77(5)) irrespective of trial outcome. |
| |
+----------------------------------------------------------------------------------------------------+
Key Differences: US 21 CFR Part 50 vs. EU MDR Article 63
| Regulatory Domain | US FDA (21 CFR Part 50 / 812) | EU MDR (Regulation (EU) 2017/745) | Operational Impact on Dual-Region Trials |
|---|---|---|---|
| Who Signs the Form? | Subject or LAR only (50.27(a)). (Investigator signature is standard practice but not CFR-mandated). | Both the subject/LAR and the person conducting the interview (Article 63(1)). | EU forms must have dual signature blocks; missing interviewer signature is an MDR non-compliance finding. |
| Deliberation Time | "Sufficient opportunity to consider" (50.20). | Express statutory requirement for "adequate time" between interview and signature (Article 63(1)). | Ethics committees check time stamps; same-minute interview and signing in elective device trials is heavily flagged. |
| Damage Compensation | Required only for > minimal risk; states whether treatment/compensation exists (50.25(a)(6)). | Mandatory disclosure of the national insurance/guarantee system under Article 69 (Article 63(2)(d)). | EU ICF must name the specific insurance policy, coverage limits, and claims filing procedure for that Member State. |
| Study Identification Code | NCT number on ClinicalTrials.gov (50.25(c)). | Single Identification Number (CIV-ID) under Article 70(1) (Article 63(2)(e)). | EU ICF must explicitly display the CIV-ID generated upon initial clinical investigation application. |
| Lay Summary Publication | Results posted to ClinicalTrials.gov (technical summary). | Mandatory disclosure that a Layperson Summary will be published in EUDAMED under Article 77(5) (Article 63(6)). | EU ICF must promise lay summary availability regardless of whether the trial succeeds, fails, or is terminated early. |
| Withdrawal of Consent | Subject may discontinue at any time without penalty (50.25(a)(8)). | Revoke consent at any time without detriment and without justification (Article 62(5)). | Data collected prior to withdrawal is retained; post-withdrawal implant management must be addressed. |
| Emergency Research Pathway | 21 CFR 50.24 EFIC (community consultation, public disclosure, separate IDE). | MDR Article 68 (Informed consent in emergency situations). | Article 68 allows emergency enrollment if therapeutic window prevents consent, followed by prompt post-enrollment consent. |
Special Populations Under EU MDR (Articles 64–67)
The MDR imposes strict, population-specific consent safeguards:
- Incapacitated Subjects (Article 64): Permissible only if the investigation directly benefits the subject or produces population-level benefit with minimal risk/burden; assent must be sought from the subject to the extent possible, and their explicit wish to refuse must be respected.
- Minors (Article 65): Pediatric device investigations require informed consent from the legally designated representative, alongside the minor's assent (tested according to age and maturity); no financial incentives or inducements are permitted.
- Pregnant and Breastfeeding Women (Article 66): Permissible only where the device trial holds direct benefit for the woman or fetus, or produces research benefit without alternative populations and with minimal risk.
- Emergency Situations (Article 68): Where prior consent is impossible due to urgency, consent must be sought from the subject or representative as soon as possible after intervention.
Device-Native Consent Challenges: Implants, Sham Controls, and Drug-Template Bloat
A 2025 narrative review published in Medical Devices (Auckland) (Peycheva et al., PMC12311233) compared ICF requirements across jurisdictions (US, EU, UK, Taiwan, Malaysia) and issued a 20-item checklist. Its form-quality finding: informed consent forms "have grown lengthier and more complex," and device developers "have followed the same trend," partly through "trying to mimic the drug studies as best practice" and reliance on consultants used to lengthy drug-development documents. Its device-specific corrections include separate disease-related and device-related risk sections, disclosure of the device's market status and procedure-related risks, and explicit withdrawal consequences for implanted devices.
+----------------------------------------------------------------------------------------------------+
| THE 4 DEVICE-SPECIFIC INFORMED CONSENT TRAPS |
+----------------------------------------------------------------------------------------------------+
| |
| [ TRAP 1: THE IMPLANT RETENTION DILEMMA ] |
| * Subject withdraws consent, but the physical device is permanent (e.g., vascular stent). |
| * Solution: ICF must separate research data collection withdrawal from ongoing medical care |
| and clarify that the device will not be explanted if removal carries surgical risk. |
| |
| [ TRAP 2: CONFLATING PROCEDURE VS. DEVICE RISKS ] |
| * Grouping surgical incision risks with device software/mechanical risks in one long list. |
| * Solution: Provide two distinct risk tables: (A) Delivery/Surgical Risks vs. (B) Device Risks. |
| |
| [ TRAP 3: SHAM-CONTROLLED DISCLOSURE ] |
| * Blinding subjects to simulated surgical incisions or mock device activations. |
| * Solution: Clearly explain the sham procedure, probability of randomization, and unblinding |
| crossover provisions without unblinding the study. |
| |
| [ TRAP 4: POST-TRIAL DEVICE ACCESS & SOFTWARE UPDATES ] |
| * Failing to disclose who maintains the device or provides software patches after study end. |
| * Solution: Explicitly define post-study device support, warranty, and monitoring transition. |
| |
+----------------------------------------------------------------------------------------------------+
1. The Implant Withdrawal Dilemma
When a patient withdraws consent from an orthopedic knee implant or cardiac lead study:
- Data Retention: Under both FDA guidance and EU MDR Article 62(5), data gathered before consent revocation remains part of the study database to preserve scientific validity.
- The Physical Implant: The subject cannot be forced to have the device surgically removed if explantation poses physical danger. The ICF must clearly state:
"If you decide to withdraw from the study, you will not have to undergo surgery to remove the implanted device unless your doctor determines it is medically necessary for your safety. However, our study doctors will ask to continue monitoring your health for safety purposes."
2. Separating Procedural Risks from Device Performance Risks
In a catheter-delivered heart valve trial, patients face two distinct risk categories:
- Procedural/Surgical Risks: Bleeding at the femoral puncture site, infection, adverse reaction to contrast dye, anesthesia complications.
- Device-Specific Risks: Valve migration, paravalvular leak, structural valve deterioration, leaflet thrombosis, conduction abnormalities requiring a permanent pacemaker.
Grouping these into a single 15-page narrative creates cognitive overload. High-quality device consent forms present separate risk tables clearly differentiating what can happen during surgery from what can happen over years of device wear.
3. Sham-Controlled Device Trials
Designing an ethical ICF for a sham-controlled surgical or invasive trial requires disclosing the use of sham controls without compromising blinding:
- The ICF must explicitly explain that the subject has a defined chance (e.g., 50%) of receiving a simulated procedure (e.g., skin incision without device placement, or mock catheter deployment).
- The form must detail the risks of the sham procedure itself (anesthesia, procedural pain).
- It must outline whether subjects randomized to the sham arm will be offered crossover to the active device after primary endpoint completion. For comprehensive design rules, see our sham-controlled medical device clinical trials guide.
When Do Subjects Need to Be Re-Consented, and What Happens on Early Termination?
Informed consent is a continuous process. Over the multi-year lifecycle of a medical device clinical trial, new safety information emerges, protocols are amended, and trials occasionally stop early.
+----------------------------------------------------------------------------------------------------+
| RE-CONSENT TRIGGERS AND DOCUMENTATION WORKFLOW |
+----------------------------------------------------------------------------------------------------+
| |
| [ RE-CONSENT TRIGGER 1: SIGNIFICANT NEW SAFETY INFORMATION (21 CFR 50.25(b)(5)) ] |
| * Newly observed UADEs, revised risk frequencies, safety advisories, competitor recalls. |
| * Action: IRB-approved revised ICF or Consent Addendum; re-consent ALL active subjects promptly. |
| |
| [ RE-CONSENT TRIGGER 2: PROTOCOL AMENDMENTS MODIFYING SUBJECT BURDEN ] |
| * Added invasive procedures, increased radiation exposure (CT scans), extra follow-up visits. |
| * Action: Full revised ICF re-signed prior to performing the new protocol procedures. |
| |
| [ RE-CONSENT TRIGGER 3: AGE OF MAJORITY TRANSITION ] |
| * Pediatric subject enrolled under parental permission reaches legal age of majority (e.g., 18). |
| * Action: Subject must be re-consented as an adult using the approved adult ICF. |
| |
| [ STUDY TERMINATION / EARLY CLOSEOUT NOTIFICATION ] |
| * Trial suspended or terminated early (safety, business, or futility). |
| * Action: Inform subjects of reasons; provide clinical transition plan; publish EUDAMED report. |
| |
+----------------------------------------------------------------------------------------------------+
What Triggers Mandatory Re-Consent?
- Significant New Findings (21 CFR 50.25(b)(5)): If new safety data emerges—such as an increased incidence of lead perforation or a new device warning issued in another country—investigators must provide this information to currently enrolled subjects whose willingness to continue participation may be affected.
- Major Protocol Amendments: Adding new diagnostic imaging (increasing radiation dose), extending the follow-up period from 12 months to 36 months, or introducing additional blood draws requires formal re-consent before those procedures are executed.
- Transition to Adulthood: Pediatric subjects who turn 18 (or the local age of legal majority) while still enrolled must be re-consented as adults using the full adult consent document.
Minor vs. Major Changes: Full ICF vs. Consent Addendum
- Consent Addendum / Information Letter: For newly identified long-term risks where active subjects have already completed the surgical phase and are in passive follow-up, an IRB may approve a concise 2-page "Consent Addendum" or informational letter rather than forcing subjects to re-read a 25-page master ICF.
- Full Revised ICF: Required whenever active interventional procedures or ongoing clinical visit schedules change.
What Happens When a Trial Stops Early?
When a medical device study terminates prematurely—whether due to safety signals, sponsor insolvency, or futility (see our trial termination reasons analysis):
- Subject Notification: Investigators must notify subjects immediately, provide a clear explanation of why the trial stopped, and ensure an orderly clinical follow-up plan for implanted devices.
- EU Transparency Mandate (MDR Article 77(5) & 63(6)): In the European Union, early termination does not waive transparency. Sponsors must submit the clinical investigation report and a layperson summary to EUDAMED within 3 months of premature termination (compared to 1 year for standard completion).
Empirical Enforcement Analysis: What Do FDA Warning Letters Actually Cite Device Firms For?
To evaluate real-world regulatory compliance, we scanned the full text of 3,643 FDA Warning Letters issued between January 2021 and July 2026 (MedDeviceGuide analysis of the public warning-letter corpus; snapshot taken July 31, 2026).
+----------------------------------------------------------------------------------------------------+
| |
| FDA WARNING LETTER EMPIRICAL SCAN: INFORMED CONSENT CITATIONS |
| |
| * Total Warning Letters Scanned in Corpus: 3,643 |
| * Total Letters with Informed Consent Failure Language: 29 |
| |
| [ REGULATION BREAKDOWN ACROSS THE 29 CONSENT LETTERS ] |
| * 21 CFR Part 312 (Pharmaceutical IND Studies): 23 Letters |
| * 21 CFR Part 812: 4 Letters - three device sponsors (ExThera Medical, |
| United Health Products, Nobles Medical Technology II) plus one IRB |
| letter (MIT) whose Bioresearch Monitoring scope text references Part 812 |
| * Remaining 2 Letters: IRB-side citations under Part 56 / Part 50 |
| |
| [ SECTION-LEVEL CITATION DISTRIBUTION ] |
| * 21 CFR 50.20 (General Consent Duty / Exculpatory Language): 12 Letters |
| * 21 CFR 50.23 (Single Emergency Use): 11 Letters |
| * 21 CFR 50.24 (EFIC Emergency Research): 11 Letters |
| * 21 CFR 50.25 (Required Elements): 4 Letters |
| * 21 CFR 50.27 (Documentation & Signature): 4 Letters |
| |
+----------------------------------------------------------------------------------------------------+
Method note: counts reflect letters whose text contains the consent language and the cited section, including regulatory-scope boilerplate; they are not adjudicated violations of each section. Warning letters are the severe tail of enforcement and say nothing about how often consent failures occur across all trials.
Named Consent Enforcement Cases: Three Device Sponsors and One IRB
The three device-sponsor letters and the one IRB letter behind the Part 812 count above show four distinct failure modes:
1. ExThera Medical Corporation (Warning Letter CMS 715068, February 6, 2026)
- Violation: Sponsor failed to provide evidence for verification and attestation that informed consent was signed for enrolled subjects.
- Details: During a May 30, 2025 inspection, FDA asked the firm to document that informed consent was obtained from enrolled subjects in the PURIFY Study (IDE G210074) and OSCAR Study (IDE G230144); the firm could not produce the evidence and later signed an affidavit confirming it was "unable to provide such evidence." FDA framed the failure under the sponsor's monitoring and investigator-compliance duties of 21 CFR 812.40 and 812.46(a) — precisely the consent-verification failure mode that risk-based monitoring is designed to catch.
2. United Health Products, Inc. (Warning Letter CMS 697777, March 24, 2025)
- Violation: Failure to ensure investigators obtained informed consent according to the investigational plan and Part 50.
- Details: An FDA inspection of the firm's significant-risk HemoStyp study revealed that the site's protocol deviation log recorded three (3) subjects whose informed consent forms were not signed by the subject. This violated protocol inclusion criteria, 21 CFR 812.100, and 21 CFR Part 50. The sponsor failed to act upon these protocol deviations during routine monitoring (see our protocol deviations guide).
3. Nobles Medical Technology II, Inc. (Warning Letter CMS 673465, January 26, 2024)
- Violation: Inadequate informed consent forms, lack of signed investigator agreements, and inadequate monitoring.
- Details: FDA cited extensive systemic non-compliance, noting that inadequate informed consent and flawed study oversight compromised the rights, safety, and welfare of human subjects, resulting in study suspension.
4. MIT IRB (Warning Letter CMS 663218, June 21, 2024) — IRB-Side Case
- Violation: The IRB failed to require that information given to subjects as part of informed consent was in accordance with 21 CFR 50.25 (21 CFR 56.109(b)).
- Details: This is an IRB-side letter — its Bioresearch Monitoring review scope references Parts 50, 56, and 812 — not a device-manufacturer citation. The IRB approved ICFs that omitted the disclosure of appropriate alternative procedures or courses of treatment under 21 CFR 50.25(a)(4) and failed to require the injury-compensation disclosure of 50.25(a)(6) for a more-than-minimal-risk investigation. The lesson for device sponsors: IRBs reviewing device investigations own element-level consent review, and a form that reaches subjects without 50.25(a) completeness is a joint finding waiting to happen.
Sponsor Operational Playbook: 6 Informed Consent Failure Modes & SOP Implementation
To avoid costly warning letters, inspection citations, or study suspensions, clinical operations and regulatory affairs teams should integrate these six preventive controls into their clinical standard operating procedures (SOPs):
+----------------------------------------------------------------------------------------------------+
| THE 6 INFORMED CONSENT FAILURE MODES & CONTROLS |
+----------------------------------------------------------------------------------------------------+
| |
| [ FAILURE MODE 1: ENROLLING BEFORE IRB/EC APPROVAL OF REVISED ICF ] |
| * Risk: Using expired or unapproved versions of consent forms after protocol amendments. |
| * Control: Implement eTMF / eConsent version locking; EDC blocks randomization if the active |
| ICF version date does not match the latest IRB/EC approval letter. |
| |
| [ FAILURE MODE 2: MISSING INVESTIGATOR SIGNATURE ON EU MDR FORMS ] |
| * Risk: Subject signs, but interviewer signature block is left blank (violating MDR Art. 63(1)). |
| * Control: Dual-signature verification checklist during 100% first-subject monitoring visit. |
| |
| [ FAILURE MODE 3: INADEQUATE LAR DOCUMENTATION ] |
| * Risk: Enrolling incapacitated subjects with signature from unauthorized family members. |
| * Control: Establish state-by-state and country-specific LAR qualification SOPs in the CIP. |
| |
| [ FAILURE MODE 4: OMISSIONS IN EFIC COMMUNITY CONSULTATION ] |
| * Risk: Starting emergency research without Docket 95S-0158 filings or prior written FDA approval.|
| * Control: Gate enrollment on formal receipt of FDA's written authorization letter (812.20(a)(4)).|
| |
| [ FAILURE MODE 5: MISAPPLYING 50.22 MINIMAL-RISK WAIVER TO IDE TRIALS ] |
| * Risk: Claiming a waiver of consent for interventional or significant-risk device studies. |
| * Control: Legal gatekeeper: 50.22 waivers are strictly restricted to minimal-risk investigations.|
| |
| [ FAILURE MODE 6: FAILURE TO RE-CONSENT AFTER SAFETY SIGNALS ] |
| * Risk: Accumulating UADEs without updating active subjects under 21 CFR 50.25(b)(5). |
| * Control: Medical monitor review of all UADEs against active ICF risk disclosures quarterly. |
| |
+----------------------------------------------------------------------------------------------------+
The Sponsor-Site Consent Verification Checklist
Before opening site enrollment, clinical project managers should audit their consent package against this 10-point checklist:
- IRB/EC Approval Letter: Verified that the exact version date on the ICF matches the approval letter.
- Basic Elements Check (US): Verified all 8 elements of 21 CFR 50.25(a) are explicitly present.
- Verbatim ClinicalTrials.gov Statement: Verified exact 4-sentence text of 21 CFR 50.25(c).
- EU MDR Specifics (if EU sites): Dual signature lines, Article 69 damage compensation details, CIV-ID code, and Article 63(6) EUDAMED lay-summary promise included.
- Device vs. Procedure Risk Separation: Risks of surgery clearly separated from risks of device malfunction/wear.
- Implant Withdrawal Language: Explicitly states what happens to the physical device and historical data if the subject revokes consent.
- Short-Form Process (if applicable): Independent witness identified; IRB-approved written summary available.
- e-Consent Validation (if electronic): System validated under 21 CFR Part 11; audit trails and identity verification active.
- Monitoring Plan Integration: Protocol mandates 100% informed consent verification at initial monitoring visit.
- TMF Storage: Signed consent forms filed securely at site; verified by monitor without taking confidential patient identifiers off-site.
Frequently Asked Questions (FAQs)
Can a medical device trial reuse a pharmaceutical informed consent template?
No. Copying a drug trial consent template causes severe compliance gaps in device investigations. Drug templates do not separate procedural surgical risks from device mechanical risks, fail to explain what happens to an implanted device if consent is withdrawn, omit post-study device support terms, and lack device-specific regulatory references (such as 21 CFR Part 812 or EU MDR Article 63).
Is the ClinicalTrials.gov statement mandatory in every U.S. device consent form?
Yes, for all Applicable Clinical Trials. Under 21 CFR 50.25(c), any applicable device clinical trial — generally a prospective clinical study of health outcomes comparing a device intervention against a control; small feasibility trials and prototype-device trials are excluded — must include the exact 4-sentence verbatim statement required by federal law. Omitting or altering this statement violates the regulation.
Can informed consent be obtained electronically in a medical device study?
Yes. Under joint FDA and OHRP guidance, sponsors may use electronic informed consent (eIC). However, the electronic platform must comply with 21 CFR Part 11 (electronic signatures, audit trails, secure authentication) and must verify the identity of the signer.
Does an implanted investigational device have to be removed if a subject withdraws consent?
No. A subject may revoke consent to research at any time, but they cannot be compelled to undergo surgical explantation if removal carries medical risk. Under FDA guidance and EU MDR Article 62(5), data collected prior to withdrawal is retained, and the ICF must outline how the subject's long-term medical safety will be managed after withdrawal.
Is the EFIC emergency research pathway available for non-significant risk (NSR) devices?
No. Under 21 CFR 812.20(a)(1), any clinical investigation conducted under 21 CFR 50.24 (Exception From Informed Consent) is automatically classified as a Significant Risk (SR) investigation. It requires a full IDE application and prior written FDA authorization.
Who signs first on an EU MDR consent form?
Under EU MDR Article 63(1), both the person conducting the informed consent interview (the investigator or authorized delegate) and the subject (or LAR) must sign and date the consent document. While the regulation does not prescribe the millisecond sequence, both signatures must be completed during the interview process, and the subject must be afforded adequate time to deliberate.
Summary & Key Takeaways
- Informed Consent is a Continuous Communication Process: Consent is not a one-time signature event. It requires clear communication at an understandable reading level, ongoing dialogue, and timely re-consent whenever new safety findings or protocol changes emerge.
- Strict Adherence to 21 CFR 50.25: U.S. device ICFs must contain all 8 basic elements of 50.25(a), appropriate additional elements of 50.25(b), and the exact verbatim ClinicalTrials.gov statement of 50.25(c).
- The 2024 Minimal-Risk Waiver (50.22): IRBs can only waive or alter informed consent for investigations meeting all 5 criteria of 21 CFR 50.22 (effective January 22, 2024). Significant-risk interventional device trials never qualify.
- The EFIC Device Gateway (50.24 & Part 812): Planned emergency research without consent requires a separate full IDE application, prior written FDA authorization (30-day clock), prominent cover-sheet marking, community consultation, public disclosure, and an independent DMC.
- EU MDR Article 63 is Stricter Than U.S. Law: EU investigations require dual signatures (interviewer + subject), statutory disclosure of the Article 69 national damage-compensation system, display of the Article 70(1) CIV-ID, and an explicit promise that a layperson summary will be published in EUDAMED under Article 77(5).
- Device-Native Adaptation is Mandatory: Medical device consent forms must separate surgical delivery risks from device performance risks, define post-withdrawal implant management, and avoid copying bloated drug-trial templates.
- Empirical Enforcement Shows Zero Tolerance: FDA inspections actively cite sponsors for missing consent forms (ExThera 2026), unsigned ICFs on deviation logs (United Health Products 2025), and inadequate IRB-approved risk disclosures (MIT IRB 2024). Rigorous monitoring and version-controlled eTMF processes are essential.
References & Official Sources
- 21 CFR Part 50 — Protection of Human Subjects (eCFR consolidated text).
- 21 CFR Part 812 — Investigational Device Exemptions (eCFR consolidated text).
- FDA Final Rule: Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations (88 FR 88228, Dec 21, 2023) (Docket FDA-2018-N-2727).
- FDA Final Guidance: Informed Consent — Guidance for IRBs, Clinical Investigators, and Sponsors (August 2023).
- FDA Final Guidance: Exception from Informed Consent Requirements for Emergency Research (April 2013) (Docket FDA-2006-D-0464).
- FDA / OHRP Joint Guidance: Use of Electronic Informed Consent in Clinical Investigations (December 2016) (81 FR 90855).
- FDA CDRH: IDE Informed Consent Guidance.
- Regulation (EU) 2017/745 (EU MDR) Articles 62–69 & 77 (EUR-Lex official text).
- ISO 14155:2026 — Clinical investigation of medical devices for human subjects — Good clinical practice (ISO Online Browsing Platform).
- Peycheva et al., Enhancing Informed Consent Forms for Medical Devices: International Regulatory Guidance and Ethical Recommendations, Medical Devices (Auckland) 2025;18:397-411.
- FDA Warning Letter CMS 715068 — ExThera Medical Corporation (February 6, 2026).
- FDA Warning Letter CMS 697777 — United Health Products, Inc. (March 24, 2025).